Download PDF
Thromb Haemost 2004; 91(05): 1050
DOI: 10.1055/s-0037-1614203
Letters to the Editor
Schattauer GmbH

Mechanism of action of drotrecogin alfa activated (rhAPC)

Bernd Jilma
,
Ulla Derhaschnig
Further Information

Publication History

Received 17 December 2003

Accepted 09 February 2004

Publication Date:
15 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Dhainaut JF, Yan SB, Margolis BD. et al. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003; 90 (04) 642-53.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Bernard GR, Vincent JL, Laterre PF. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344 (10) 699-709.
    CrossrefPubMedGoogle Scholar
  • 3 Crowther MA, Marshall JC. Continuing challenges of sepsis research. JAMA 2001; 286 (15) 1894-6.
    CrossrefPubMedGoogle Scholar
  • 4 Angus DC, Crowther MA. Unraveling severe sepsis: why did OPTIMIST fail and what’s next?. JAMA 2003; 290 (02) 256-8.
    CrossrefPubMedGoogle Scholar
  • 5 Derhaschnig U, Reiter R, Knobl P. et al. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxe-mia. Blood 2003; 102 (06) 2093-8.
    CrossrefPubMedGoogle Scholar
  • 6 Taylor Jr F. Comment on “Drotrecogin Alfa (activated) (recombinant human protein C, rhAPC) reduces host coagulopathy response in patients with severe sepsis”. Thromb Haemost 2003; 90 (04) 560-1.
    Article in Thieme ConnectPubMedGoogle Scholar